AOD-9604: What Happened in the Weight-Loss Trials?
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
Tesamorelin is often discussed online as a way to lose belly fat. Its established medical use is much narrower: a specialist condition affecting some adults with HIV. The fat measurements in those studies are not the same as body-weight loss.

Tesamorelin is a medicine that stimulates the body’s release of growth hormone. In the United States, it is used under the Egrifta name for a specific problem: excess abdominal fat in adults with HIV-associated lipodystrophy.
Lipodystrophy means an abnormal distribution of body fat. It is a medical condition, not simply another name for having a larger waist. The evidence for tesamorelin needs to be read in that setting.
The US prescribing information for Egrifta WR explicitly says it is not indicated for weight-loss management. Its use for a specialist condition should not be presented as approval for general weight loss.
The Care Pharmacy does not offer tesamorelin. This guide explains why claims about “belly fat” can be misleading and what the clinical evidence actually measured.
Studies have found reductions in visceral fat in selected adults with HIV and excess abdominal fat. Visceral fat sits deeper inside the abdomen, around internal organs. It differs from the fat directly under the skin.
In a 26-week trial involving 412 people with HIV, visceral fat fell by 15.2% with tesamorelin and increased by 5.0% with placebo. The researchers assessed fat using scans. Those percentages do not describe total body-weight loss.
That distinction is easily lost online. A 15% reduction in a particular fat measurement is not the same as losing 15% of your starting weight. A person weighing 100kg should not read that result as a prediction of losing 15kg.
Nor does the study establish that tesamorelin is an appropriate treatment for anyone who wants a smaller waist. The participants had a particular diagnosis and were assessed for a specialist trial. Applying their results to the general population would go beyond what was tested.
A smaller trial reported in JAMA studied visceral and liver fat in people with HIV and abdominal fat accumulation. It found reductions in these measurements over six months, but the authors said more research was needed to understand their long-term importance.
Research into liver fat does not mean a medicine has been approved for every form of fatty liver disease. The diagnosis, study population and outcome all matter. A change on a scan also does not automatically establish fewer heart attacks, a longer life or improved day-to-day symptoms.
An additional trial with an extension period found that the improvement in visceral fat was lost quickly in participants switched to placebo. That study also assessed body composition and how participants felt about their appearance. Its main question was not how much overall weight people could lose. That is relevant when considering how long treatment effects last. It does not provide a self-treatment plan or establish long-term safety.
These studies help clinicians understand a specific medicine in a specific clinical setting. They do not turn it into a general-purpose fat-loss product.
Tesamorelin affects growth-hormone signalling and can raise IGF-1, a growth factor. The US label calls for monitoring and identifies concerns including glucose intolerance or diabetes, fluid retention, joint symptoms and allergic reactions.
It also lists important restrictions, including active cancer and pregnancy. These are not details that can be checked safely from a seller’s short product description. Treatment decisions require a clinician who knows the patient’s history and can arrange appropriate follow-up.
Long-term cardiovascular safety has not been established. A reduction in visceral fat should therefore not be described as proof of heart protection.
Buying a vial online adds separate uncertainties about what it contains, its strength and how it has been made or stored. A product sold as a research chemical is not made suitable for personal use by including a laboratory report.
If you have used a peptide bought online, tell a healthcare professional what you took and when. Keep the packaging or a photograph if you have it. If you become unwell, seek medical advice rather than taking another product to try to counteract the effects.
Our check of the MHRA medicines database found no tesamorelin product record. The Care Pharmacy does not supply it or offer a consultation for obtaining it.
You may find US prescribing information when searching from the UK. A US approval applies to its stated indication in that country. It is not evidence of UK authorisation or of approval for general weight management.
The European application for Egrifta was withdrawn in 2012. That is a historical regulatory decision, not a current UK treatment recommendation. It should not be confused with a medicine being withdrawn from all use worldwide.
If you have HIV and are concerned about changes in body fat, speak to your HIV clinic. They can assess the cause and discuss care in the context of your treatment. Do not stop or change antiretroviral medicines yourself.
The phrase can sound reassuringly precise, especially if the scales have hardly changed but your waist is worrying you. Yet an appearance concern is not enough to identify the cause or choose a medicine.
A larger abdomen can reflect several things, and a photograph cannot tell you how much visceral fat you have. Sudden or unexplained swelling, pain or a rapid change in shape should be assessed medically rather than assumed to be ordinary weight gain.
Claims about metabolism, growth hormone or fat burning also need evidence in the people being encouraged to use the product. A plausible explanation of how a compound works is not the same as a successful trial showing worthwhile benefits and acceptable harms.
For general weight management, it makes more sense to consider treatments with evidence and an authorised use relevant to your health. You can discuss those options without buying a peptide first.
If your main concern is overweight or obesity, a weight-management assessment is different from specialist care for HIV-associated lipodystrophy. The NHS information on overweight and obesity describes the range of support, including medicines where appropriate.
A prescriber should consider your medical history, current medicines and previous attempts to manage your weight. Tell them about any underlying condition or specialist team involved in your care. That helps avoid treating one concern without considering the rest of your health.
You can ask what a proposed medicine is licensed for, what benefit is realistic and how treatment will be reviewed. You should also know who to contact about side effects and what ongoing private care costs. Being interested in a medicine is a useful starting point for a conversation, not a reason to skip the assessment.
The often-quoted figure concerns visceral-fat measurements in a specialist HIV trial. It should not be presented as a 15% reduction in total body weight.
No. Tesamorelin works through growth-hormone release. It is different from semaglutide and tirzepatide, which act on other hormone pathways.
No. Approval is for a defined use, and suitability still requires individual assessment. The US label does not indicate tesamorelin for general weight-loss management.
No. The consultation is for assessing currently offered weight-loss treatment. The Care Pharmacy does not offer tesamorelin.
If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.
This guide gives general information. Ask a qualified healthcare professional about your own treatment.
Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.
Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.
Medically reviewed by
Superintendent Pharmacist
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
Research into MOTS-c does not all answer the same question. This guide separates studies of the body’s own peptide from claims about taking it.
CJC-1295 and ipamorelin are often discussed together. Evidence for each substance should not be confused with evidence for the combination.
Can you get Wegovy on the NHS in Scotland? See how advice differs for injections and tablets and what to ask your local health board.
Can you get Wegovy on the NHS in Wales? Learn what Level 3 weight management means and how to ask your local health board about a referral.
Looking into Wegovy in Guildford? See how to ask about a specialist NHS referral and where to find local weight management support in Surrey.